 Glucogon-like peptid-1, GLP-1, is an incretin hormone produced by intestinal L-cells in response to nutrients. It plays a key role in regulating blood sugar levels by stimulating insulin production from pancreatic beta cells, slowing down digestion, reducing glucogon levels and reducing appetite. GLP-1 based treatments are being used to manage type 2 diabetes due to their ability to lower blood sugar levels. Recently, researchers have discovered that these treatments can also reduce inflammation in various chronic inflammatory conditions, such as type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, non-alcoholic steetohibatis, diabetic nephropathy, asthma, and psoriasis. These treatments work by activating specific cellular pathways that reduce inflammation and promote healing. This article was authored by Yang Sun-li and Heesuk Jang.